Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 164 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo inhalation solution Clear all

Conditions: Pneumonia, Bacterial
Interventions: Amikacin Inhalation Solution (BAY41-6551), Aerosolized Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 32
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 27 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 84
States / cities: Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Arformoterol Tartrate Inhalation Solution, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Medford, Oregon • Portland, Oregon • Philadelphia, Pennsylvania + 1 more

Conditions: Cystic Fibrosis
Interventions: AZLI 75 mg three times a day (TID), Placebo three times a day (TID); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 40
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Glyocopyrrolate Inhalation Solution administered by Magnair, Placebo administered by Magnair; Combination Product · Drug
Lead sponsor: Sunovion Respiratory Development Inc.; Industry
Eligibility: 40 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Placebo matching Olodaterol, Olodaterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 94
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 82 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sodium Nitrite Inhalation Solution, Placebo and AIR001 Inhalation Solution (Expansion arm); Drug
Lead sponsor: Aires Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium Inhalation Solution, Placebo; Drug · Other
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 9 more

Conditions: Asthma
Interventions: Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 50
States / cities: Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more

Conditions: COVID-19
Interventions: PUL-042 Inhalation Solution, Placebo; Drug
Lead sponsor: Pulmotect, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Orange, California • San Bernardino, California • Coral Gables, Florida + 7 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 92
States / cities: Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more

Conditions: Cystic Fibrosis
Interventions: BI 1265162, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Orlando, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 5 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Treprostinil Inhalation Solution, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Chronic Obstructive Pulmonary Disease, COPD
Interventions: TD-4208, Placebo; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Cystic Fibrosis
Interventions: Aeroquin, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 95
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 82 more

Conditions: Exercise-Induced Laryngeal Obstruction, Dyspnea During Activity
Interventions: Ipratropium Bromide, Normal Saline (Placebo); Drug
Lead sponsor: Cook Children's Health Care System; Other
Eligibility: 8 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Prosper, Texas

Conditions: Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions: Arformoterol Tartrate Inhalation Solution, Tiotropium, Arformoterol and Tiotropium, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 28
States / cities: Jasper, Alabama • Tucson, Arizona • San Diego, California + 25 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: MP-376, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 39
States / cities: Haleyville, Alabama • Hueytown, Alabama • Mobile, Alabama + 36 more

Conditions: Anxiety
Interventions: Testosterone, Placebo; Drug
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Emphysema, Alpha 1-Antitrypsin Deficiency
Interventions: Hyaluronic Acid Inhalation Solution, Placebo Inhalation Solution; Drug
Lead sponsor: Gerard Turino; Individual
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Miami, Florida • Fayetteville, New York • Charleston, South Carolina + 2 more

Conditions: Cystic Fibrosis
Interventions: P-1037, Hypertonic Saline, Saline; Drug
Lead sponsor: Parion Sciences; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 33
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 30 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol; Device · Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 15
States / cities: Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more

Conditions: Asthma
Interventions: n-acetylcystine + albuterol, 0.9% saline + albuterol; Combination Product
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cystic Fibrosis
Interventions: AZLI, Placebo to match AZLI, Tobramycin inhalation solution; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more

Search by objective public record fields.

Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers

Tiotropium / Respimat One-Year Study

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Effect of Ipratropium Bromide on EILO

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients

Effects of Fast Acting Testosterone Nasal Spray on Anxiety

Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency

Clearing Lungs With Epithelial Sodium Channel (ENaC) Inhibition in Cystic Fibrosis (CF)

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

The Effect of NAC on Lung Function and CT Mucus Score

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF